Patient demographics and transplant characteristics
| Characteristics . | No iron overload . | Iron overload . | P . |
|---|---|---|---|
| N | 28 | 60 | |
| Median age (range), y | 52 (19-70) | 52 (20-69) | .85 |
| Male gender | 23 (82%) | 37 (62%) | .05 |
| HCT comorbidity index | .12 | ||
| 0 | 17 (61%) | 30 (50%) | |
| 1-2 | 3 (11%) | 14 (23%) | |
| ≥3 | 5 (18%) | 15 (25%) | |
| Missing | 3 (10%) | 1 (2%) | |
| Diagnosis | <.01 | ||
| ALL | 1 (4%) | 9 (15%) | |
| AML | 3 (11%) | 24 (40%) | |
| MDS | 4 (14%) | 11 (18%) | |
| Lymphoma | 7 (25%) | 12 (20%) | |
| Multiple myeloma | 7 (25%) | 1 (2%) | |
| Other | 6 (21%) | 3 (5%) | |
| High disease risk | 21 (75%) | 24 (40%) | <.01 |
| Conditioning regimen | .46 | ||
| Myeloablative | 5 (18%) | 15 (25%) | |
| Reduced intensity | 23 (82%) | 45 (75%) | |
| Graft source | .11 | ||
| Marrow | 5 (18%) | 5 (8%) | |
| PBSCs | 14 (50%) | 22 (37%) | |
| UCB | 9 (32%) | 33 (55%) | |
| Donor type | .11 | ||
| Matched sibling | 14 (50%) | 20 (33%) | |
| Matched unrelated | 5 (18%) | 6 (10%) | |
| Mismatched unrelated | 0 | 1 (2%) | |
| Single UCB | 0 | 1 (2%) | |
| Double UCB | 9 (32%) | 32 (53%) | |
| Gender-mismatched graft | 18 (64%) | 39 (65%) | .95 |
| ABO blood match | .79 | ||
| Match | 12 (43%) | 24 (40%) | |
| Minor mismatch | 6 (21%) | 10 (17%) | |
| Major mismatch | 9 (32%) | 25 (42%) | |
| CMV serostatus | .03 | ||
| Patient−/donor− | 12 (43%) | 15 (25%) | |
| Patient−/donor+ | 5 (18%) | 4 (7%) | |
| Patient+ | 11 (39%) | 41 (68%) |
| Characteristics . | No iron overload . | Iron overload . | P . |
|---|---|---|---|
| N | 28 | 60 | |
| Median age (range), y | 52 (19-70) | 52 (20-69) | .85 |
| Male gender | 23 (82%) | 37 (62%) | .05 |
| HCT comorbidity index | .12 | ||
| 0 | 17 (61%) | 30 (50%) | |
| 1-2 | 3 (11%) | 14 (23%) | |
| ≥3 | 5 (18%) | 15 (25%) | |
| Missing | 3 (10%) | 1 (2%) | |
| Diagnosis | <.01 | ||
| ALL | 1 (4%) | 9 (15%) | |
| AML | 3 (11%) | 24 (40%) | |
| MDS | 4 (14%) | 11 (18%) | |
| Lymphoma | 7 (25%) | 12 (20%) | |
| Multiple myeloma | 7 (25%) | 1 (2%) | |
| Other | 6 (21%) | 3 (5%) | |
| High disease risk | 21 (75%) | 24 (40%) | <.01 |
| Conditioning regimen | .46 | ||
| Myeloablative | 5 (18%) | 15 (25%) | |
| Reduced intensity | 23 (82%) | 45 (75%) | |
| Graft source | .11 | ||
| Marrow | 5 (18%) | 5 (8%) | |
| PBSCs | 14 (50%) | 22 (37%) | |
| UCB | 9 (32%) | 33 (55%) | |
| Donor type | .11 | ||
| Matched sibling | 14 (50%) | 20 (33%) | |
| Matched unrelated | 5 (18%) | 6 (10%) | |
| Mismatched unrelated | 0 | 1 (2%) | |
| Single UCB | 0 | 1 (2%) | |
| Double UCB | 9 (32%) | 32 (53%) | |
| Gender-mismatched graft | 18 (64%) | 39 (65%) | .95 |
| ABO blood match | .79 | ||
| Match | 12 (43%) | 24 (40%) | |
| Minor mismatch | 6 (21%) | 10 (17%) | |
| Major mismatch | 9 (32%) | 25 (42%) | |
| CMV serostatus | .03 | ||
| Patient−/donor− | 12 (43%) | 15 (25%) | |
| Patient−/donor+ | 5 (18%) | 4 (7%) | |
| Patient+ | 11 (39%) | 41 (68%) |
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; PBSCs, peripheral blood stem cells; UCB, umbilical cord blood.